Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.

• Status: Recruiting
• Trial end date: 2025-11-30
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this double-blind clinical trial is to compare the efficacy of octreotide versus placebo in laparoscopic hepatectomy surgery in patients diagnosed with resectable hepatocarcinoma or liver metastases.

The main questions it aims to answer are:

• Decrease in intraoperative bleeding measured in ml of blood lost.

• Decrease in the need for blood transfusion and use of intraoperative vasoactive drugs.

Participants will receive octreotide or placebo after signing the informed consent form.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
• Treatments: Octreotide

Criteria

Inclusion Criteria:

• Patients diagnosed with hepatic lesions who are going to undergo hepatectomy via laparoscopy.

• The patient must be between 18 and 80 years old.

• The patient, or his/her representative, has given his/her consent to participate in the study.

• The patient must, in the opinion of the investigator, be able to comply with all the requirements of the clinical trial.

• The patient must not be allergic to the drug.

Exclusion Criteria:

• History of hypersensitivity to the drug to be administered.

• Children under 18 years of age.

• Urgent intervention.

• Intervention performed in an open manner (not laparoscopic).

• Patient's refusal to participate in the study.

• Contraindication to receive octreotide.

• Women of childbearing age (those women who are in the period between menarche and menopause). Having to present a negative pregnancy test to take part in the study.

• Pregnant or lactating women, given the absence of studies of this drug in this patient profile.